JPRN-UMIN000048156招募中未知
HEMLIBRA Subcutaneous Injection, General drug use-results survey - Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia A - - HEMLIBRA Subcutaneous Injection, General drug use-results survey - Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia A
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
不适用
HEMLIBRA Subcutaneous injection General Drug Use Surveillance(in Hemophilia A with Inhibitors).Hemophilia AJPRN-UMIN000032515Chugai Pharmaceutical Co. Ltd.100
已完成
不适用
HEMLIBRA Subcutaneous injection Special Drug Use Surveillance (with Hemophilia A without Inhibitors).Hemophilia AJPRN-UMIN000037503Chugai Pharmaceutical Co. Ltd.87
招募中
Unknown
EPKINLY Subcutaneous Injection General use-results surveillance (All case): OBSC3013-39D-ERelapsed or refractory large B-cell lymphoma and relapsed or refractory follicular lymphomaJPRN-jRCT2031230525Genmab K.K. Drug safety and pharmacovigilance250
招募中
2 期
effects of rituximab in patients with pemphigus vulgaris with oral lesionsIRCT20240604062002N1Tabriz University of Medical Sciences20
进行中（未招募）
不适用
Efficacy and Safety of subcutaneous administration of XM01 and Epoetin beta for treatment of anaemia in chronic renal failure patients not yet receiving dialysis. A multinational, multicentre, randomised, controlled, double-blind, parallel group phase II study.EUCTR2005-000140-85-HUBioGeneriX AG150